Brownfield Science & Technology Inc. Honored for Professional…

Brownfield Science & Technology Inc. (BSTI) was awarded with the Greater Philadelphia Chamber of Commerce’s Professional Services Excellence of the Year Award.(PRWeb January 01, 2013)Read the full story at http://www.prweb.com/releases/2013/1/…



Brownfield Science & Technology Inc. Honored for Professional…

Brownfield Science & Technology Inc. (BSTI) was awarded with the Greater Philadelphia Chamber of Commerce’s Professional Services Excellence of the Year Award.(PRWeb January 01, 2013)Read the full story at http://www.prweb.com/releases/2013/1/…



Rudy Mazzocchi Prepares to Release the Second Thriller in The EQUITY…

Within one year of the release of his award-winning Thriller, EQUITY of EVIL, Mazzocchi announces the pending release of the second novel in this trilogy based on the existence of revolutionary…(PRWeb January 01, 2013)Read the full story at http:/…



A snapshot of the successful bio-clusters around the world: Lessons for South African biotechnology

Development of clusters has been one of the critical factors in the success of many countries in the field of biotechnology. Most of the literature has been focused on the biotechnology clusters in developed countries and much less attention has been p…



Improving IPO market still not an exit path

Recent suggestions that improving IPO activity will lead biotech venture investors to lucrative exits seems to be a bit premature and detached from the reality of these deals. The maxim oft repeated by venture investors has never been truer: IPOs are f…



China’s heparin revisited: What went wrong and has anything changed?

China is the world’s largest producer of crude heparin. In 2007, tainted Chinese crude heparin made its way into the global finished heparin supply chain killing 149 persons in 11 different countries including 81 deaths in the US. While China never f…



Biotechnology valuation and governance: Drug development and board of directors composition

This paper examines the valuation of biotechnology firms and measure firm value relative to the firms’ drug development pipelines, alliances with other firms, and the varied composition of those firms’ boards of directors.  Unsurprisingly, the adv…